Olodanrigan (EMA401) is a highly selective, orally active, peripherally restrictedangiotensin II type 2 receptor (AT2R)antagonist. It is under development as a neuropathic pain therapeutic agent. Olodanrigan (EMA401) analgesic action appears to involve inhibition of augmented AngII/AT2R induced p38 and p42/p44 MAPK activation, and hence inhibition of DRG neuron hyperexcitability and sprouting of DRG neurons^[1][2][3][4].

EMA401 (10 mg/kg; p.o.) results in a significant attenuation of theta power and increase in paw withdrawal latencies (PWL) in rats at day 14 after chronic constriction injury (CCI)^[4].

507.58

Solid

C₃₂H₂₉NO₅

1316755-16-4

Room temperature in continental US; may vary elsewhere.

DMSO : ≥ 34 mg/mL(66.98 mM)

H₂O : 0.1 mg/mL(0.20 mM;Need ultrasonic)

*"≥" means soluble, but saturation unknown.

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。